Patents by Inventor Julia Lynn RUTKOWSKI
Julia Lynn RUTKOWSKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11918647Abstract: The present invention relates to peptides that bind with high specificity and which functionally interact with the transferrin receptor (“TfR”) and which may be used in making molecular vehicles that carry biomolecules across membranes, including, e.g., across the blood brain barrier or the gastrointestinal tract. TfR specific binding moieties may also be used alone or as components in specific molecules that target the transferrin/transferrin receptor transport system. The invention relates more specifically to VNAR single chain antibodies derived from nurse shark that bind to TfR, compounds and compositions comprising a TfR specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use in vitro or in vivo, e.g., to diagnose, treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to deliver a heterologous biomolecule across the blood brain barrier by association with a TfR specific VNAR binding moiety.Type: GrantFiled: June 25, 2020Date of Patent: March 5, 2024Assignee: OSSIANIX, INC.Inventors: Julien Hasler, Julia Lynn Rutkowski, Krzysztof Bartlomiej Wicher
-
Publication number: 20240050581Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to the methods used to identify membrane receptors or transporters capable of carrying cargo specifically targeted to the parenchymal tissue of the brain and to in vivo enrichment methods for selecting peptides that are transported across the blood-brain barrier (“BBB”), or analogously, across other membrane containing organs or structures, such as liver, spleen, kidney and tumors.Type: ApplicationFiled: August 11, 2023Publication date: February 15, 2024Applicant: Ossianix, Inc.Inventors: Pawel STOCKI, Krzysztof Bartlomiej WICHER, Julia Lynn RUTKOWSKI, Fabrizio COMPER, Mykhaylo DEMYDCHUK, Jaroslaw Michal SZARY
-
Publication number: 20240026022Abstract: The present invention relates to a high affinity, VNAR polypeptide cross reactive with primate transferrin receptors (“TfR”). This TfR-specific VNAR polypeptide was obtained by screening semisynthetic VNAR phage display libraries against recombinant human TfR-1. The VNAR polypeptides of the invention can be used alone or as a component in conjugates that target the transferrin/transferrin receptor transport system. The invention further includes use of this VNAR, its conjugates and other derivatives in diagnostic and therapeutic methods, e.g., to diagnose, treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to deliver a heterologous biomolecule across the blood brain barrier or other membrane systems. This TfR-specific VNAR polypeptide can also be used to target other biological barriers such the intestines, the placenta or aberrant cells overexpressing TfR-1, for therapeutic benefit in treatment of certain cancer cells and tumors of various tissue types.Type: ApplicationFiled: September 11, 2021Publication date: January 25, 2024Inventors: Pawel STOCKI, Jaroslaw Michal SZARY, Krzysztof Bartlomiej WICHER, Laura THEI, Julia Lynn RUTKOWSKI, Mykhaylo DEMYDCHUK, Shu-Fen COKER
-
Patent number: 11766482Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to the methods used to identify membrane receptors or transporters capable of carrying cargo specifically targeted to the parenchymal tissue of the brain and to in vivo enrichment methods for selecting peptides that are transported across the blood-brain barrier (“BBB”), or analogously, across other membrane containing organs or structures, such as liver, spleen, kidney and tumors.Type: GrantFiled: July 21, 2021Date of Patent: September 26, 2023Assignee: Ossianix, Inc.Inventors: Pawel Stocki, Krzysztof Bartlomiej Wicher, Julia Lynn Rutkowski, Fabrizio Comper, Mykhaylo Demydchuk, Jaroslaw Michal Szary
-
Publication number: 20230183369Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to improved TfR-binding moieties based on shark VNARs capable of crossing the blood brain barrier (BBB) and capable of carrying and releasing cargo specifically targeted to the parenchymal tissue of the brain.Type: ApplicationFiled: October 27, 2022Publication date: June 15, 2023Applicant: OSSIANIX, INC.Inventors: Pawel STOCKI, Krzysztof Bartlomiej WICHER, Jaroslaw Michal SZARY, Julia Lynn RUTKOWSKI
-
Publication number: 20230000998Abstract: The present disclosure relates to conjugates for delivering therapeutics across the blood brain barrier (BBB) and more particularly to conjugates comprising at least one BBB-shuttling VNAR domain operably linked to a neurotrophic agonist antibody (NAAb), with the conjugate being capable of uptake across a mammalian blood brain barrier (BBB) in a therapeutically-effective amount. These conjugates are useful for treating neurodegenerative diseases, conditions which responds to activation of a neurotrophin receptor as well as for stimulating neuronal survival, growth, repair or regeneration.Type: ApplicationFiled: November 20, 2020Publication date: January 5, 2023Applicant: OSSIANIX, INC.Inventors: Julia Lynn Rutkowski, Frank Walsh, Elizabeth H. Sinclair, Pawel Stocki
-
Patent number: 11512136Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to improved TfR-binding moieties based on shark VNARs capable of crossing the blood brain barrier (BBB) and capable of carrying and releasing cargo specifically targeted to the parenchymal tissue of the brain.Type: GrantFiled: October 27, 2018Date of Patent: November 29, 2022Assignee: Ossianix, Inc.Inventors: Pawel Stocki, Krzysztof Bartlomiej Wicher, Jaroslaw Michal Szary, Julia Lynn Rutkowski
-
Publication number: 20220177597Abstract: The present invention relates to CD98hc binding moieties with high specificity and with ability to cross the blood brain barrier (BBB). Such moieties may be used alone or as components in specific conjugates that target the amino acid transporter complexes formed with a light chain and CD98hc. The invention relates more specifically to VNAR single chain antibodies derived from nurse shark that bind to CD98hc, compounds and compositions comprising a CD98hc-specific binding moiety, diagnostic and therapeutic methods of use in vitro or in vivo, e.g., to diagnose, treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to deliver a heterologous biomolecule across the blood brain barrier by association with a CD98hc-specific VNAR binding moiety. The invention also includes Type IV semi-synthetic VNAR libraries derived from shark VNARs for selection of binding moieties that specifically bind to a molecular or cellular target of interest.Type: ApplicationFiled: June 19, 2019Publication date: June 9, 2022Applicant: Ossianix, Inc.Inventors: Krzysztof Bartlomiej Wicher, Jaroslaw Michal Szary, Julia Lynn Rutkowski, Fabrizio Comper, Pawel Stocki
-
Patent number: 11345742Abstract: The present disclosure provides coronavirus S1-fragment specific binding moieties comprising Type II VNAR domains, VNAR antibodies, methods of using those moieties and antibodies to treat COVID-19. In some embodiments, a VNAR antibody, originally selected from a phage display library as a VNAR clone using S1fragments from the SARS-CoV-2 Wuhan strain, are also effective at specifically binding to and/or neutralizing SARS-CoV-2 and certain SARS-CoV-2 mutants.Type: GrantFiled: June 9, 2021Date of Patent: May 31, 2022Assignee: Ossianix, Inc.Inventors: Aziz Gauhar, Cyril V. Privezentzev, Pawel Stocki, Julia Lynn Rutkowski
-
Patent number: 11339389Abstract: The present invention relates to VNAR single chain antibodies and more particularly, to semi-synthetic VNAR libraries derived from nurse shark which may be used to identify individual clones, nucleic acid molecules and polypeptides which encode binding moieties that specifically bind to a cellular target of interest, thereby altering (e.g., antagonizing) target activity in a cell or mimicking the activity of a native molecule. The present invention thus also relates to compounds and compositions comprising a target specific VNAR binding moiety, methods for preparing them, and diagnostic and therapeutic methods of use relating to regulation, e.g., agonism or antagonism of the selected cellular target or target pathway e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to alter, e.g., agonize or augment, antagonize, reduce or eliminate the specific cellular target activity.Type: GrantFiled: October 3, 2019Date of Patent: May 24, 2022Assignee: Ossianix, Inc.Inventors: Julien Häsler, Julia Lynn Rutkowski
-
Patent number: 11267894Abstract: The present invention relates to peptide antagonists that bind with high specificity and affinity to B-Lymphocyte stimulator (“BAFF”), thereby antagonizing BAFF receptor (“BAFF-R”) signaling. The invention more specifically relates to VNAR single chain antibodies derived from nurse shark that bind to BAFF, BAFF antagonist compounds and compositions comprising a BAFF specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo B cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete B cells, such as in autoimmune diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) or multiple sclerosis (MS), and in certain hematological cancers, including lymphomas, leukemias and myelomas.Type: GrantFiled: August 21, 2019Date of Patent: March 8, 2022Assignee: Ossianix, Inc.Inventors: Julien Häsler, Julia Lynn Rutkowski
-
Publication number: 20220031857Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to the methods used to identify membrane receptors or transporters capable of carrying cargo specifically targeted to the parenchymal tissue of the brain and to in vivo enrichment methods for selecting peptides that are transported across the blood-brain barrier (“BBB”), or analogously, across other membrane containing organs or structures, such as liver, spleen, kidney and tumors.Type: ApplicationFiled: July 21, 2021Publication date: February 3, 2022Applicant: Ossianix, Inc.Inventors: Pawel STOCKI, Krzysztof Bartlomiej WICHER, Julia Lynn RUTKOWSKI, Fabrizio COMPER, Mykhaylo DEMYDCHUK, Jaroslaw Michal SZARY
-
Publication number: 20210403591Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to improved TfR-binding moieties based on shark VNARs capable of crossing the blood brain barrier (BBB) and capable of carrying and releasing cargo specifically targeted to the parenchymal tissue of the brain.Type: ApplicationFiled: October 27, 2018Publication date: December 30, 2021Applicant: Ossianix, Inc.Inventors: Pawel STOCKI, Krzysztof Bartlomiej WICHER, Jaroslaw Michal SZARY, Julia Lynn RUTKOWSKI
-
Publication number: 20210395381Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to improved TfR-binding moieties capable of crossing the blood brain barrier (BBB) and capable of carrying and releasing cargo specifically targeted to the parenchymal tissue of the brain. The present invention relates to a transcytosis selection method to obtain VNARs against mammalian blood brain barrier (BBB) receptors using phage display libraries as well as against receptors found in other directional cell barrier systems like the gastrointestinal tract and other organs. The VNARs may be used alone or as components in compositions or as conjugates that target the particular receptor transport systems for delivery of therapeutics or diagnostics to the brain (in the case of BBB receptors) or other tissues.Type: ApplicationFiled: September 13, 2019Publication date: December 23, 2021Inventors: Krzysztof B. Wicher, Julia Lynn Rutkowski, Pawel Stocki
-
Patent number: 11097010Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to the methods used to identify membrane receptors or transporters capable of carrying cargo specifically targeted to the parenchymal tissue of the brain and to in vivo enrichment methods for selecting peptides that are transported across the blood-brain barrier (“BBB”), or analogously, across other membrane containing organs or structures, such as liver, spleen, kidney and tumors.Type: GrantFiled: August 4, 2017Date of Patent: August 24, 2021Assignee: Ossianix, Inc.Inventors: Pawel Stocki, Krzysztof Bartlomiej Wicher, Julia Lynn Rutkowski, Fabrizio Comper, Mykhaylo Demydchuk, Jaroslaw Michal Szary
-
Publication number: 20200316195Abstract: The present invention relates to peptides that bind with high specificity and which functionally interact with the transferrin receptor (“TfR”) and which may be used in making molecular vehicles that carry biomolecules across membranes, including, e.g., across the blood brain barrier or the gastrointestinal tract. TfR specific binding moieties may also be used alone or as components in specific molecules that target the transferrin/transferrin receptor transport system. The invention relates more specifically to VNAR single chain antibodies derived from nurse shark that bind to TfR, compounds and compositions comprising a TfR specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use in vitro or in vivo, e.g., to diagnose, treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to deliver a heterologous biomolecule across the blood brain barrier by association with a TfR specific VNAR binding moiety.Type: ApplicationFiled: June 25, 2020Publication date: October 8, 2020Applicant: Ossianix, Inc.Inventors: Julien HASLER, Julia Lynn Rutkowski, Krzysztof Bartlomiej WICHER
-
Patent number: 10722576Abstract: The present invention relates to peptides that bind with high specificity and which functionally interact with the transferrin receptor (“TfR”) and which may be used in making molecular vehicles that carry biomolecules across membranes, including, e.g., across the blood brain barrier or the gastrointestinal tract. TfR specific binding moieties may also be used alone or as components in specific molecules that target the transferrin/transferrin receptor transport system. The invention relates more specifically to VNAR single chain antibodies derived from nurse shark that bind to TfR, compounds and compositions comprising a TfR specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use in vitro or in vivo, e.g., to diagnose, treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to deliver a heterologous biomolecule across the blood brain barrier by association with a TfR specific VNAR binding moiety.Type: GrantFiled: May 14, 2017Date of Patent: July 28, 2020Assignee: Ossianix, Inc.Inventors: Julien Häsler, Julia Lynn Rutkowski, Krzysztof Bartlomiej Wicher
-
Publication number: 20200115702Abstract: The present invention relates to VNAR single chain antibodies and more particularly, to semi-synthetic VNAR libraries derived from nurse shark which may be used to identify individual clones, nucleic acid molecules and polypeptides which encode binding moieties that specifically bind to a cellular target of interest, thereby altering (e.g., antagonizing) target activity in a cell or mimicking the activity of a native molecule. The present invention thus also relates to compounds and compositions comprising a target specific VNAR binding moiety, methods for preparing them, and diagnostic and therapeutic methods of use relating to regulation, e.g., agonism or antagonism of the selected cellular target or target pathway e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to alter, e.g., agonize or augment, antagonize, reduce or eliminate the specific cellular target activity.Type: ApplicationFiled: October 3, 2019Publication date: April 16, 2020Applicant: Ossianix, Inc.Inventors: Julien HÄSLER, Julia Lynn RUTKOWSKI
-
Publication number: 20200024354Abstract: The present invention relates to peptide antagonists that bind with high specificity and affinity to B-Lymphocyte stimulator (“BAFF”), thereby antagonizing BAFF receptor (“BAFF-R”) signaling. The invention more specifically relates to VNAR single chain antibodies derived from nurse shark that bind to BAFF, BAFF antagonist compounds and compositions comprising a BAFF specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo B cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete B cells, such as in autoimmune diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) or multiple sclerosis (MS), and in certain hematological cancers, including lymphomas, leukemias and myelomas.Type: ApplicationFiled: August 21, 2019Publication date: January 23, 2020Applicant: Ossianix, Inc.Inventors: Julien HÄSLER, Julia Lynn RUTKOWSKI
-
Patent number: 10479990Abstract: The present invention relates to VNAR single chain antibodies and more particularly, to semi-synthetic VNAR libraries derived from nurse shark which may be used to identify individual clones, nucleic acid molecules and polypeptides which encode binding moieties that specifically bind to a cellular target of interest, thereby altering (e.g., antagonizing) target activity in a cell or mimicking the activity of a native molecule. The present invention thus also relates to compounds and compositions comprising a target specific VNAR binding moiety, methods for preparing them, and diagnostic and therapeutic methods of use relating to regulation, e.g., agonism or antagonism of the selected cellular target or target pathway e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to alter, e.g., agonize or augment, antagonize, reduce or eliminate the specific cellular target activity.Type: GrantFiled: June 26, 2015Date of Patent: November 19, 2019Assignee: Ossianix, Inc.Inventors: Julien Häsler, Julia Lynn Rutkowski